Drug Profile
Onametostat - Johnson & Johnson
Alternative Names: JNJ-64619178Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Antineoplastics; Cyclopentanes; Pyrimidines; Pyrroles; Quinolines; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Late-stage disease) in Canada (PO, Capsule)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Late-stage disease) in Germany (PO, Capsule)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Late-stage disease) in Israel (PO, Capsule)